Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Lung Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 71 articles: HTML format

Single Articles

November 2023
1. TRAN HT, Heeke S, Sujit S, Vokes N, et al
   Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer.
   Ann Oncol. 2023 Nov 20:S0923-7534(23)05072-X. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
2. SHIRAISHI Y, Sekino Y, Horinouchi H, Ohe Y, et al
   High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab.
   Ann Oncol. 2023;34:1064-1065.
   PubMed    
   
   
   October 2023
3. BORGHAEI H, de Marinis F, Dumoulin D, Reynolds C, et al
   SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Advanced Non-Squamous Non-Small Cell Lung Cancer.
   Ann Oncol. 2023 Oct 11:S0923-7534(23)04019-X. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
4. JOHN A, Popat S
   Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
   Ann Oncol. 2023;34:829-830.
   PubMed    
   
   
   
5. GOUDA MA, Hu MI, Cabanillas ME, Wu J, et al
   Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
   Ann Oncol. 2023;34:946-948.
   PubMed    
   
   
   August 2023
6. BESSE B, Felip E, Campelo RG, Cobo M, et al
   Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.
   Ann Oncol. 2023 Aug 1:S0923-7534(23)00790-1. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   July 2023
7. FELIP E, Altorki N, Zhou C, Vallieres E, et al
   Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
   Ann Oncol. 2023 Jul 17:S0923-7534(23)00764-0. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
8. BOIARSKY D, Lydon CA, Chambers ES, Sholl LM, et al
   Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
   Ann Oncol. 2023;34:589-604.
   PubMed     Abstract available
   
   
   
9. RAKAEE M, Andersen S, Giannikou K, Paulsen EE, et al
   Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
   Ann Oncol. 2023;34:578-588.
   PubMed     Abstract available
   
   
   June 2023
10. BAZHENOVA L
    Corrigendum to "Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level": [Annals of Oncology 34 (2023) 327-332].
    Ann Oncol. 2023 Jun 7:S0923-7534(23)00688-9. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    May 2023
11. BUROTTO M, Zvirbule Z, Mochalova A, Runglodvatana Y, et al
    IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-
    Ann Oncol. 2023 May 31:S0923-7534(23)00694-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
12. CHOUAID C, Gendarme S, Auliac JB
    Artificial intelligence to finally enable precision medicine for the management of resected non-small cell lung cancer.
    Ann Oncol. 2023 May 12:S0923-7534(23)00675-0. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    April 2023
13. BAZHENOVA L
    Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level.
    Ann Oncol. 2023;34:327-332.
    PubMed    
    
    
    
14. MOK TSK, Lopes G, Cho BC, Kowalski DM, et al
    Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Ann Oncol. 2023;34:377-388.
    PubMed     Abstract available
    
    
    March 2023
15. SCALERA S, Ricciuti B, Mazzotta M, Calonaci N, et al
    Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
    Ann Oncol. 2023;34:275-288.
    PubMed     Abstract available
    
    
    February 2023
16. REMON J, Besse B, Aix SP, Callejo A, et al
    Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
    Ann Oncol. 2023 Feb 28:S0923-7534(23)00089-3. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    January 2023
17. MALVEZZI M, Santucci C, Boffetta P, Collatuzzo G, et al
    EUROPEAN CANCER MORTALITY PREDICTIONS FOR THE YEAR 2023 WITH FOCUS ON LUNG CANCER.
    Ann Oncol. 2023 Jan 27:S0923-7534(23)00048-0. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
18. HENDRIKS LE, Kerr KM, Menis J, Mok TS, et al
    Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2023 Jan 23:S0923-7534(22)04781-0. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
19. HENDRIKS LE, Kerr KM, Menis J, Mok TS, et al
    Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2023 Jan 3:S0923-7534(22)04785-8. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
20. REICHERT ZR, Morgan TM, Li G, Castellanos E, et al
    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
    Ann Oncol. 2023;34:111-120.
    PubMed     Abstract available
    
    
    December 2022
21. SELENICA P, Marra A, Choudhury NJ, Gazzo A, et al
    APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
    Ann Oncol. 2022;33:1284-1295.
    PubMed     Abstract available
    
    
    November 2022
22. BORGHAEI H, Ciuleanu TE, Lee JS, Pluzanski A, et al
    Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.
    Ann Oncol. 2022 Nov 19:S0923-7534(22)04740-8. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available
    
    
    
23. CORTELLINI A, Barrichello APC, Alessi JV, Ricciuti B, et al
    A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions.
    Ann Oncol. 2022;33:1202-1204.
    PubMed    
    
    
    
24. MCGRAIL DJ, Pilie PG, Rashid NU, Voorwerk L, et al
    Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
    Ann Oncol. 2022;33:1204-1206.
    PubMed    
    
    
    October 2022
25. PEYRAUD F, Guegan JP, Bodet D, Nafia I, et al
    Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
    Ann Oncol. 2022;33:1041-1051.
    PubMed     Abstract available
    
    
    September 2022
26. DIMITRIOU F, Namikawa K, Reijers ILM, Buchbinder EI, et al
    Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
    Ann Oncol. 2022;33:968-980.
    PubMed     Abstract available
    
    
    August 2022
27. GRIESINGER F, Curigliano G, Thomas M, Subbiah V, et al
    Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.
    Ann Oncol. 2022 Aug 13. pii: S0923-7534(22)03866.
    PubMed     Abstract available
    
    
    
28. LUO J, Wu S, Rizvi H, Zhang Q, et al
    Deciphering radiological stable disease to immune checkpoint inhibitors.
    Ann Oncol. 2022;33:824-835.
    PubMed     Abstract available
    
    
    
29. ZHANG FL, Song SS, Wang J, Zhang P, et al
    First-generation EGFR-TKI in refractory metastatic alveolar soft part sarcoma with EGFR alteration: a case report.
    Ann Oncol. 2022;33:847-848.
    PubMed    
    
    
    July 2022
30. RICCIUTI B, Alessi JV, Elkrief A, Wang X, et al
    Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D) mutated non-small cell lung cancer.
    Ann Oncol. 2022 Jul 21. pii: S0923-7534(22)01856.
    PubMed     Abstract available
    
    
    
31. SHAO XM, Huang J, Niknafs N, Balan A, et al
    HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Ann Oncol. 2022;33:728-738.
    PubMed     Abstract available
    
    
    June 2022
32. CORTIULA F, Reymen B, Peters S, Van Mol P, et al
    Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches.
    Ann Oncol. 2022 Jun 28. pii: S0923-7534(22)01742.
    PubMed     Abstract available
    
    
    
33. BRUNET M, Crombe A, Cousin S, Vanhersecke L, et al
    Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01736.
    PubMed    
    
    
    May 2022
34. CEDRES S, Felip E
    3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma.
    Ann Oncol. 2022;33:457-459.
    PubMed    
    
    
    
35. SUBBIAH V, Iannotti NO, Gutierrez M, Smith DC, et al
    FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Ann Oncol. 2022;33:522-533.
    PubMed     Abstract available
    
    
    
36. PETERS S, Scherpereel A, Cornelissen R, Oulkhouir Y, et al
    First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
    Ann Oncol. 2022;33:488-499.
    PubMed     Abstract available
    
    
    April 2022
37. CHEN J, Facchinetti F, Braye F, Yurchenko AA, et al
    Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
    Ann Oncol. 2022;33:434-444.
    PubMed     Abstract available
    
    
    March 2022
38. ROSELL R, Cardona AF, Arrieta O, Gonzalez-Cao M, et al
    Classification of atypical EGFR mutations in non-small cell lung cancer.
    Ann Oncol. 2022 Mar 21. pii: S0923-7534(22)00389.
    PubMed    
    
    
    
39. JANNING M, Suptitz J, Albers-Leischner C, Delpy P, et al
    Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
    Ann Oncol. 2022 Mar 6. pii: S0923-7534(22)00361.
    PubMed     Abstract available
    
    
    February 2022
40. GALE D, Heider K, Ruiz-Valdepenas A, Hackinger S, et al
    Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
    Ann Oncol. 2022 Feb 26. pii: S0923-7534(22)00123.
    PubMed     Abstract available
    
    
    
41. PEROL M, Felip E, Dafni U, Polito L, et al
    Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data.
    Ann Oncol. 2022 Feb 23. pii: S0923-7534(22)00124.
    PubMed     Abstract available
    
    
    
42. PASSARO A, Leighl N, Blackhall F, Popat S, et al
    ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.
    Ann Oncol. 2022 Feb 14. pii: S0923-7534(22)00112.
    PubMed     Abstract available
    
    
    
43. REMON J, Hendriks LEL, Bironzo P
    Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease.
    Ann Oncol. 2022;33:123-125.
    PubMed    
    
    
    
44. POPAT S, Baas P, Faivre-Finn C, Girard N, et al
    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
    Ann Oncol. 2022;33:129-142.
    PubMed    
    
    
    
45. SOO RA, Han JY, Dafni U, Cho BC, et al
    A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER tria
    Ann Oncol. 2022;33:181-192.
    PubMed     Abstract available
    
    
    January 2022
46. PASTORINO U, Boeri M, Sestini S, Sabia F, et al
    Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial.
    Ann Oncol. 2022 Jan 25. pii: S0923-7534(22)00017.
    PubMed     Abstract available
    
    
    
47. NOVELLO S, Torri V, Grohe C, Kurz S, et al
    Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-
    Ann Oncol. 2022 Jan 24. pii: S0923-7534(22)00014.
    PubMed    
    
    
    
48. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available
    
    
    
49. KOK IC, Hooiveld JS, van de Donk PP, Giesen D, et al
    (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
    Ann Oncol. 2022;33:80-88.
    PubMed     Abstract available
    
    
    December 2021
50. WAUTERS E, Vansteenkiste J
    Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding.
    Ann Oncol. 2021;32:1463-1465.
    PubMed    
    
    
    
51. TOPP BG, Thiagarajan K, De Alwis DP, Snyder A, et al
    Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.
    Ann Oncol. 2021;32:1618-1625.
    PubMed     Abstract available
    
    
    November 2021
52. ATTILI I, Passaro A, de Marinis F
    Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials.
    Ann Oncol. 2021 Nov 25. pii: S0923-7534(21)04823.
    PubMed    
    
    
    
53. NIU J, Maurice-Dror C, Lee DH, Kim DW, et al
    First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.
    Ann Oncol. 2021 Nov 17. pii: S0923-7534(21)04776.
    PubMed     Abstract available
    
    
    October 2021
54. CHOW A, Hellmann MD
    Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer.
    Ann Oncol. 2021 Oct 26. pii: S0923-7534(21)04549.
    PubMed    
    
    
    
55. FEDERICO L, McGrail DJ, Bentebibel SE, Haymaker C, et al
    Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer.
    Ann Oncol. 2021 Oct 12. pii: S0923-7534(21)04519.
    PubMed     Abstract available
    
    
    
56. NOVELLO S, Torri V, Grohe C, Kurz S, et al
    International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung
    Ann Oncol. 2021 Oct 5. pii: S0923-7534(21)04496.
    PubMed     Abstract available
    
    
    
57. SHITARA K, Lunceford J
    Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.
    Ann Oncol. 2021;32:1303-1304.
    PubMed    
    
    
    September 2021
58. PETERS S, Pujol JL, Dafni U, Domine M, et al
    Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
    Ann Oncol. 2021 Sep 22. pii: S0923-7534(21)04490.
    PubMed     Abstract available
    
    
    
59. DICKSON JL, Horst C, Nair A, Tisi S, et al
    Hesitancy around low dose CT screening for lung cancer.
    Ann Oncol. 2021 Sep 20. pii: S0923-7534(21)04487.
    PubMed     Abstract available
    
    
    
60. SCHOENFELD AJ, Antonia SJ, Awad MM, Felip E, et al
    Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2021 Sep 3. pii: S0923-7534(21)04455.
    PubMed     Abstract available
    
    
    
61. SAW SPL, Tan DSW
    Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future.
    Ann Oncol. 2021;32:1075-1076.
    PubMed    
    
    
    
62. FOOTE MB, Maron SB, Cercek A, Argiles G, et al
    TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.
    Ann Oncol. 2021;32:1188-1189.
    PubMed    
    
    
    August 2021
63. REMON J, Soria JC, Peters S
    Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.
    Ann Oncol. 2021 Aug 28. pii: S0923-7534(21)04279.
    PubMed    
    
    
    
64. CORTELLINI A, Ricciuti B, Facchinetti F, Alessi JVM, et al
    Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Ann Oncol. 2021 Aug 13. pii: S0923-7534(21)03973.
    PubMed     Abstract available
    
    
    July 2021
65. RODRIGUEZ-ABREU D, Powell SF, Hochmair MJ, Gadgeel S, et al
    Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
    Ann Oncol. 2021;32:881-895.
    PubMed     Abstract available
    
    
    June 2021
66. SUGAWARA S, Lee JS, Kang JH, Kim HR, et al
    Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ann Oncol. 2021 Jun 14. pii: S0923-7534(21)02052.
    PubMed     Abstract available
    
    
    
67. RECK M, Carbone DP, Garassino M, Barlesi F, et al
    Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02045.
    PubMed     Abstract available
    
    
    
68. BARDIA A, Messersmith WA, Kio EA, Berlin JD, et al
    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Ann Oncol. 2021;32:746-756.
    PubMed     Abstract available
    
    
    May 2021
69. BLACKHALL FH
    Reframing recalcitrance for small cell lung cancer.
    Ann Oncol. 2021 May 3. pii: S0923-7534(21)01186.
    PubMed    
    
    
    
70. LACH KD, Sorin M, Huynh C, Alirezaie NS, et al
    Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis.
    Ann Oncol. 2021;32:679-681.
    PubMed    
    
    
    April 2021
71. DINGEMANS AC, Fruh M, Ardizzoni A, Besse B, et al
    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2021 Apr 9. pii: S0923-7534(21)01113.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.